← Eichor
Study identifier: NCT06668181 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Condition: Enthesitis-related Arthritis · Juvenile Psoriatic Arthritis  ·  Sponsor: UCB Biopharma SRL

PhasePhase 3
Planned participants40
Who can joinAll sexes, 2 Years to 18 Years
Healthy volunteersNo

About this study

The purpose of this study is to assess plasma bimekizumab concentrations following subcutaneous (sc) bimekizumab administration.

This description comes directly from the study's public registry record.

Talk to the study team

UCB Cares  ·  +18445992273  ·  ucbcares@ucb.com

UCB Cares  ·  001 844 599 2273

Always discuss trial participation with your own doctor first.

Locations (23)

Ja0005 50646Calgary, CanadaRecruiting
Ja0005 50644Montreal, CanadaRecruiting
Ja0005 50645Saskatoon, CanadaRecruiting
Ja0005 40777Indre-et-Loire, FranceRecruiting
Ja0005 40510Le Kremlin-Bicêtre, FranceRecruiting
Ja0005 40778Paris, FranceRecruiting
Ja0005 40776Poitiers, FranceRecruiting
Ja0005 40369Berlin, GermanyRecruiting
Ja0005 40356Dresden, GermanyRecruiting
Ja0005 40072Freiburg im Breisgau, GermanyRecruiting
Ja0005 40852Hamburg, GermanyRecruiting
Ja0005 40787Sankt Augustin, GermanyRecruiting

+ 11 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06668181